



Continuous Glucose Monitoring—Derived Data Report—Simply a Better Management Tool

Tadej Battelino^{1,2} and
Richard M. Bergenstal³

Diabetes Care 2020;43:2327–2329 | <https://doi.org/10.2337/dci20-0032>

The introduction of A1C into routine diabetes care some 30 years ago provided the first reliable marker of glycemic control, clearly related to devastating chronic complications of diabetes. A1C became the standard metric to judge the quality of diabetes care and the primary outcome for all diabetes intervention trials investigating novel medications and new technologies. This dependence on A1C as our sole glycemic management guide and primary outcome measure was questioned by some investigators (1); however, the A1C was familiar and convenient and became the key diabetes pay-for-performance quality metric in the U.S. After decades of the “A1C era” in diabetes care, it is now evident that the management of diabetes guided by A1C has not yielded our desired results, and despite novel medicines and diabetes technology the mean A1C has actually deteriorated in the last decade (2–5). As national A1C levels were slipping, an impactful article entitled “Resurgence in Diabetes-Related Complications” was published (6), pointing out that while health care access, delivery, and preventive services are far from ideal, we also need to focus on innovative strategies to safely achieve glycemic targets. It seems fair to ask, what went wrong? Wasn’t the introduction of continuous glucose

monitoring (CGM) going to transform diabetes management (7)?

While it often takes 17 years to get approved therapies or technology innovations adopted and implemented in clinical practice (8), we believe that in the case of CGM, effective implementation will also involve a refinement of our management philosophy. Our current training on use of the CGM glucose profile and data report is to always address any noted patterns of hypoglycemia first. This is a sound principle, and using CGM we have been extremely successful in minimizing hypoglycemia as demonstrated in randomized clinical trials (9–11) and cohort studies (12). Unfortunately, in routine clinical care, we often forget the word *first* in the CGM teaching principle of “address hypoglycemia *first*.” We are happy we prevented or reversed the feared and potentially dangerous condition of hypoglycemia, but then we often do not aggressively shift our focus to minimize the hyperglycemia usually also present. Maybe this is because the hyperglycemia is generally much less symptomatic and is a long-term issue that does not evoke the same urgency of attention as hypoglycemia. We seem surprised when the A1C actually drifts up or the CGM time in range (TIR) 70–180 mg/dL seems stuck at 50%

when the international consensus target for TIR is over 70%. The “zero-harm strategy” (13) of “no hypoglycemia” advocated by many may finally prove harmful by also being associated with a general increase in hyperglycemia and chronic complications of diabetes (3,6). The big question for every endocrinologist, primary care physician, nurse practitioner, pharmacist, or diabetes educator is, with the availability of CGM, are we all ready to adopt a balanced diabetes management philosophy of aggressively minimizing hyperglycemia (time above range [TAR]) and hypoglycemia (time below range [TBR]) while maximizing TIR? Would such a TIR-centric approach to the day-to-day management of diabetes finally prevent or minimize acute and chronic diabetes complications (14)?

In this issue of *Diabetes Care*, an important report by Dr. Elena Toschi and colleagues from the Joslin Diabetes Center starts with an exemplary observation: “Current guidelines for older adults with T1D [type 1 diabetes] recommend less stringent hemoglobin A_{1c} (A1C) targets to mitigate hypoglycemia. . . . However, studies have shown that liberalization of A1C may not protect against the risk of hypoglycemia in the older population” (15). Exactly! One becomes tempted to think that the current guidelines for particularly

¹University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

³International Diabetes Center at Park Nicollet and HealthPartners, Minneapolis, MN

Corresponding author: Tadej Battelino, tadej.battelino@mf.uni-lj.si

T.B. and R.M.B. contributed equally to this commentary.

© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

See accompanying article, p. 2349.

vulnerable populations simply recommend the easiest thing to do—increase the mean glucose—despite the facts that this strategy does not always prevent hypoglycemia (3) and that the resulting increase in hyperglycemia clearly inflicts additional risk. Could we do better than this?

Toschi et al. (15) divided 130 adults aged ≥65 years (mean age 71 years, mean T1D duration 39 years, mean A1C 7.3% [56 mmol/mol]) in a post hoc analysis into two groups, those with percent coefficient of variation (CV%) ≤36% and those with CV% >36%, based on 14 days of CGM data according to the consensus recommendations (16). Both groups had the same mean A1C of 7.3%. Individuals with CV% ≤36% spent significantly less time in hypoglycemia (defined as TBR<⁷⁰ [under 70 mg/dL] and TBR<⁵⁴ [under 54 mg/dL]), confirming the well-established relation between CV and TBR (17), and, importantly, also significantly less time in hyperglycemia above 250 mg/dL (TAR>²⁵⁰). If we use these data and present them according to the international consensus on clinical targets for CGM (18), we realize the value of working to improve glucose variability (CV%) in order to achieve our ultimate diabetes management goal of reaching both the consensus targets for TIR and TBR. Note that individuals with CV% ≤36% reached and exceeded targets for TBR and also

almost reached targets for TIR and TAR, while individuals with CV% >36% fell short of reaching any of the consensus targets (Fig. 1), both groups having exactly the same A1C.

Furthermore, the glucose management indicator (GMI), the CGM-derived metric reflecting the mean sensor glucose level, differed from the laboratory A1C by more than 0.5% in 46% of participants: 37% of those had a GMI greater than the corresponding A1C, and 63% had a GMI lower than the A1C. When GMI was ≥0.5% higher than the A1C, it correlated significantly with TIR and TAR>²⁵⁰, but not with TBR; conversely, when GMI was lower than A1C by ≥0.5%, it correlated significantly with TBR<⁷⁰ and TBR<⁵⁴, but not with TIR and TAR. This additionally delineated the superior sensitivity of GMI versus A1C to the time spent in respective glucose ranges that had already been demonstrated for younger populations (19,20), which may be even more important in older populations. The study by Toschi et al. provides support for the view that CGM data reports might improve management of T1D by identifying high risk through high CV, by setting more confident individual glycemic goals with assessment of the relationship between GMI and A1C, and by using TIR metrics for personalizing regimens to decrease CV. Notably, the

use of CGM data reports can also help optimize metabolic control in insulin-treated type 2 diabetes (21).

Some feel that until there is a prospective randomized controlled trial showing that CGM metrics correlate with long-term complications, we are still in the A1C era. Others are encouraged that, while indirect and preliminary, there are data showing that derived CGM metrics like TIR do correlate with long-term complications (22).

We contend that regarding the most effective approach to glucose management we have clearly moved from the A1C era into the CMG management era, but we recognize some will need a transitional time combining both. Our goal in this CGM management era is to embrace the philosophy that it is possible and essential to achieve an optimal TIR, avoiding the harmful effects of acute (23) and chronic (24) hyperglycemia, while at the same time minimizing TBR or hypoglycemia. The CGM management era is just taking shape, and we know there is work to be done on many aspects of CGM implementation into practice, including effective workflow, data integration into the electronic health record, clinical decision support, measurement of quality of life, and reduction of the burden of living with diabetes. Particularly important is ensuring equitable access to and the affordability of CGM.




Figure 1—CGM data from Toschi et al. (15) represented as bars of the consensus Ambulatory Glucose Profile (18). Numbers in bars are percentages of the daily time in respective ranges.

Funding. T.B. is supported in part by Slovene Research Agency grants J3-6798, V3-1505, and P3-0343; European Commission Innovative Medicines Initiative grants INNODIA and INNODIA-HARVEST; and National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grant UC4DK108611. R.M.B.’s technology work is supported in part by National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grant UC4DK108611, The Leona M. and Harry B. Helmsley Charitable Trust Ambulatory Glucose Profile grant, and Park Nicollet Foundation care transformation grant.

Duality of Interest. T.B. has received honoraria for participation on advisory boards for Novo Nordisk, Sanofi, Eli Lilly and Company, and Medtronic and as a speaker for AstraZeneca, Eli Lilly and Company, Novo Nordisk, Medtronic, Sanofi, Indigo, and Roche and owns stocks of DreaMed Diabetes; his institution has received research grant support and travel expenses from Abbott Diabetes Care, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz, and Diamyd. R.M.B. has received research funding and served as a consultant and on advisory boards for Abbott Diabetes Care, Ascensia, Dexcom, Eli Lilly and Company, Glooko, Hygieia, Johnson & Johnson, Medtronic,

Merck, Novo Nordisk, Onduo, Roche, Sanofi, and United Healthcare. R.M.B.'s employer, nonprofit HealthPartners Institute, contracts for his services, and no personal income goes to R.M.B. No other potential conflicts of interest relevant to this article were reported.

References

1. Wilson DM, Xing D, Beck RW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Hemoglobin A_{1c} and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. *Diabetes Care* 2011; 34:540–544
2. Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. *Diabetes Technol Ther* 2019;21:66–72
3. Pettus JH, Zhou FL, Shepherd L, et al. Incidences of severe hypoglycemia and diabetic ketoacidosis and prevalence of microvascular complications stratified by age and glycemic control in U.S. adult patients with type 1 diabetes: a real-world study. *Diabetes Care* 2019;42:2220–2227
4. Kazemian P, Shebl FM, McCann N, Walensky RP, Wexler DJ. Evaluation of the cascade of diabetes care in the United States, 2005–2016. *JAMA Intern Med* 2019;179:1376–1385
5. Fang M. Trends in diabetes management among US adults: 1999–2016. *J Gen Intern Med* 2020;35:1427–1434
6. Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. *JAMA* 2019;321:1867–1868
7. Bergenstal RM. Continuous glucose monitoring: transforming diabetes management step by step. *Lancet* 2018;391:1334–1336
8. Balas EA, Chapman WW. Road map for diffusion of innovation in health care. *Health Aff (Millwood)* 2018;37:198–204
9. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. *Diabetes Care* 2011;34:795–800
10. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes Endocrinol* 2016;4:893–902
11. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. *Lancet* 2018;391:1367–1377
12. Tauschmann M, Hermann JM, Freiberg C, et al.; DPV Initiative. Reduction in diabetic ketoacidosis and severe hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3,553 subjects from the DPV registry. *Diabetes Care* 2020;43:e40–e42
13. Meddings J, Saint S, Lilford R, Hofer TP. Targeting zero harm: a stretch goal that risks breaking the spring. *NEJM Catalyst* 2020;1. DOI: 10.1056/CAT.20.0354
14. Dovc K, Battelino T. Evolution of diabetes technology. *Endocrinol Metab Clin North Am* 2020;49:1–18
15. Toschi E, Slyne C, Sifre K, et al. The relationship between CGM-derived metrics, A1C, and risk of hypoglycemia in older adults with type 1 diabetes. *Diabetes Care* 2020;43:2349–2354
16. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. *Diabetes Care* 2017;40:1631–1640
17. Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. *Diabetes Care* 2016;39:502–510
18. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. *Diabetes Care* 2019;42:1593–1603
19. Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. *Diabetes Care* 2018;41:2275–2280
20. Carlson AL, Criego AB, Martens TW, Bergenstal RM. HbA_{1c}: the glucose management indicator, time in range, and standardization of continuous glucose monitoring reports in clinical practice. *Endocrinol Metab Clin North Am* 2020;49:95–107
21. Maiorino MI, Signoriello S, Maio A, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. *Diabetes Care* 2020;43:1146–1156
22. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. *Diabetes Care* 2019;42:400–405
23. Šuput Omladič J, Slana Ozimič A, Vovk A, et al. Acute hyperglycemia and spatial working memory in adolescents with type 1 diabetes. *Diabetes Care* 2020;43:1941–1944 DOI: 10.2337/dc20-0171
24. Bebu I, Schade D, Braffett B, et al.; DCCT/EDIC Research Group. Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT/EDIC study. *Diabetes Care* 2020;43:867–874